cerca CERCA
Lunedì 26 Luglio 2021
Aggiornato: 20:41
Temi caldi

consenso

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.

Standard Textile and Küçükçalık Announce Joint Venture to Accelerate Growth in Markets

CINCINNATI, June 24, 2021 /PRNewswire/ -- Standard Textile Co., Inc. and Küçükçalık today announce they have entered into a joint venture agreement. The joint venture agreement brings together the specialized expertise and knowledge of two leading textile manufacturing companies to expand their product portfolio and accelerate growth in the healthcare, hospitality, and consumer markets. 

CommerceHub Announces Four-Year Agreement with Foot Locker Europe to Drive Ecommerce Growth

LONDON, June 22, 2021 /PRNewswire/ -- CommerceHub, a leading ecommerce enablement platform of thousands of retailers, brands and suppliers, today announced that Foot Locker Europe has signed a four-year agreement to help expand its product assortment and create a more efficient supply chain for its Foot Locker and Sidestep brands across eighteen European countries.

Seraphim and Rodina Enters into an Agreement for Supply of 1GW PV Modules

CHANGZHOU, China, June 4, 2021 /PRNewswire/ -- On June 4, Jiangsu Seraphim Solar System Co., Ltd. (hereinafter referred to as Seraphim), a global leading PV module manufacturer, announced that it has entered into an agreement for supply of 1GW PV modules with Rodina Energy Group LLC (hereinafter referred to as Rodina), a global EPC and O&M service provider. Both parties agreed to work together to bring high quality solar products and services to global clients in order to gain a larger share of o...

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021.

Shanghai Electric Signs Agreement to Launch PEM Hydrogen Production Technology R&D Center, Empowering Green Hydrogen Development in China

SHANGHAI, March 16, 2021 /PRNewswire/ -- Shanghai Electric (the "Company") (SEHK: 02727, SSE: 601727), the world's leading manufacturer and supplier of electric power generation equipment, industrial equipment, and integration services, joined hands with the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences (the "Dalian Institute") to inaugurate the Proton Exchange Membrane (PEM) Hydrogen Production Technology R&D Center on March 4. The two parties signed a project cooperati...

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced the companies will be expanding their manufacturing agreement...

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.

Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®

NEW YORK and BLAINVILLE, QC, Nov. 30, 2020 /PRNewswire/ -- Today the Population Council and Duchesnay announce an exclusive license agreement to make ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive fully under a woman's control to protect against unintended pregnancy for up to a year, available in Canada, Europe, Latin America, Asia and other territories. This agreement is another step toward bringing contraceptive choice, convenience and con...

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

SUZHOU, China, Oct. 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications.

ora in
Prima pagina
articoli
in Evidenza